

15. Role of Health Technology Assessment in Pharmaceutical Market Access in Developed Countries

Rabia Kahveci¹, Wija Oortwijn^{2,3}, Brian Godman^{4,5,6}, E. Meltem Koç⁷, Birol Tibet⁸

¹ Ministry of Health Ankara Numune Hospital Health Technology Assessment Unit, Ankara, Turkey

² Ecorys Nederland, Rotterdam, The Netherlands

³ Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands

⁴ Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United Kingdom

⁵ Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden

⁶ Health Economics Centre, University of Liverpool Management School, Liverpool, UK.

⁷ Department of Family Medicine, Izmir Katip Celebi University, Izmir, Turkey

⁸ Department of Health Economics and Financing Policies, Turkish Institute for Health Policies, Health Institutes of Turkey, Ankara, Turkey

15.1 Introduction

Introduction and use of a health technology in a health care setting has clinical, economic, as well as organizational, social-cultural, legal and ethical impacts. Health Technology Assessment (HTA) is a multidisciplinary field that addresses these impacts, considering the healthcare context as well as available alternatives. HTA mainly aims to inform policy and clinical decision making. While systematically evaluating the effects of the health technology, HTA addresses direct and intended effects as well as the indirect and unintended effects. It is a multidisciplinary field with well-developed systematic processes and methods [1,2].

A health technology is defined as an intervention that may be used to promote health, to prevent, diagnose or treat acute or chronic disease, or for rehabilitation. Health technologies include pharmaceuticals, devices, diagnostics, procedures and other clinical, public health and organizational interventions [1,2].

Before a health technology is provided to the right patient, who could benefit from it at an affordable price, traditionally several hurdles are faced: the efficacy and safety of a health technology need to be proven; and must be produced with a high quality. These

three are necessary for marketing authorization. The fourth hurdle, being assessed for cost-effectiveness, is often a payer's requirement for reimbursement. HTA is mostly done or requested by relevant authorities to assess how the new product compares with the current alternatives and whether it adds value. Perhaps a decade ago, the distinction was more straightforward and the fourth hurdle was separated from the first three. But today the processes are more integrated and redesigned to provide earlier access to valuable technologies.

Health authorities across countries, including western countries, are finding it increasingly difficult to fund all new premium priced medicines [3]. The situation is exacerbated by changing demographics, increasing prevalence of chronic diseases especially non-communicable diseases, the continued launch of new premium priced medicines to address existing unmet need adding to therapeutic complexities, alongside population fragmentation with increasing knowledge of pharmacogenomics, as well as rising patient expectations [4-6].

In this chapter, we aim to explore HTA's role in market access with specific examples from different countries. In line with the scope of the book, we will focus on the pharmaceuticals and developed markets only. We will outline how HTA might lead to different outcomes in different settings and cover new possibilities and challenges to be addressed.

15.2 History of HTA

A healthy society plays a key role in the development of a country and this makes health services one of the most important indicators of a countries' development level [7,8]. The fundamental purpose of healthcare services is to provide the public with equal access to high quality and timely services at a sustainable cost [4,8]. The organization of healthcare and funding systems differ according to the socioeconomic conditions and political context of the relevant country [5,9].

As countries develop economically, health technologies advance rapidly. Rapid developments increase the demand for health care services, and consequently health expenditure dynamics increase [9].

The rapid diffusion of health technologies challenges governments to provide high quality, equal and accessible care for the citizens while managing the health care budgets effectively. Questions about the effectiveness of experimental technologies, as well as increased health care expenditures and restricted health care budgets, led to the development of HTA [10].

Health Technology Assessment became a concept in 1976; it initially spread from the United States (U.S.) to Western Europe and in recent years HTA is rapidly developing worldwide. In 1967, HTA was first used as a term in United States Congress [11]. In 1972, the U.S. Congressional Office of Technology Assessment (OTA) was established and OTA initiated a health program in 1974. During this program OTA pub-

lished eighty different HTA reports [12], especially focusing on efficacy, safety, and cost-effectiveness [13]. The early products of OTA and evidence based reviews derived by the Cochrane Collaboration displayed the most important roles on shaping the field of HTA.

Inspired by the reports of OTA, The Swedish Council on Technology Assessment in Health Care (SBU) started HTA development in Europe [13]. This first period of synthesizing the available evidence with efficacy and cost-effectiveness supported policy-makers in national health programmes with regard to evidence-informed decision-making [11]. After 1985, HTA has gradually spread to nearly all western and southern European countries, then to Central Europe, Latin America, and Asia. International organizations such as the World Bank, World Health Organization (WHO), International Society of Technology Assessment in Health Care (ISTAHC), its successor Health Technology Assessment International (HTAi), and the International Network of Agencies for Health Technology Assessment (INAHTA) all benefit the development and use of HTA [13].

15.3 HTA and Market Access

Market access is defined as “openness of a country’s markets to foreign goods and services” [14]. Although this is the basic definition, pharmaceutical market access can be considered as a longer and comprehensive process. This is a challenging process where many stakeholders are involved. Processes such as HTA, pricing and reimbursement; industry processes such as R&D, registration, marketing authorization and launch might impact the access process [15]. Furthermore, although there are common frameworks to demonstrate the quality, safety and efficacy of a product, there remains fragmentation regarding marketing authorization applications across the countries in Europe [5].

Due to financial crisis or economic concerns, governments face difficult times and priorities need increasingly to be set given the extent of unmet need that still exists [4,16]. Especially, the last decade has witnessed cost-cuts and increased price negotiations and in this context, HTA has been increasingly recognized to meet policymakers’ needs by providing them information on the costs and benefits of drugs. Although the focus lies on providing value for money, it has been quite hard to measure value, interpret it and have data on the appropriate impact on the outcome [17].

HTA serves the purpose of providing policymakers with reliable assessments of the pharmaceuticals that would reflect the real world, but also will aid the manufacturers to prove the value of the drugs they have produced. HTA might highlight the drugs that are expensive compared to their benefits, or might outline the indications and patient groups that would have additional value. Unsafe and ineffective drugs will also be discovered during these processes, leading to active dissemination [18-20].

15.4 HTA, Regulation, Pricing and Reimbursement of Pharmaceuticals

It is relatively easier to harmonize regulatory processes across countries, while pricing and reimbursement decisions on pharmaceuticals depend more on the local context [4,5,21]. For example, it is very difficult to translate cost-effectiveness from one setting to another. Furthermore, the political and health care context, national/regional priorities and social values differ across countries, making it more complex to transfer the outcomes of HTA evaluations. This is quite challenging for the manufacturers as they need to understand expectations of HTA organizations which may vary from country to country. To address this, for instance European countries are seeking to collaborate on HTA assessments (EUnetHTA – discussed later) as well as trying to find ways to collaborate on methodology development and approaches regarding earlier access to medicines including adaptive pathways, and several stakeholders are involved in this collaboration. The approaches will further be explored later in this chapter.

In many countries, pricing and reimbursement decisions are taken at the national level. The manufacturer needs to submit a dossier for this purpose after obtaining marketing authorization; i.e. a license issued by a medicines agency approving a medicine for market use based on a determination by authorities that the medicine meets agreed requirements of quality, safety and efficacy for human use in therapeutic treatment [5]. Many countries use HTA to subsequently guide or inform the pricing and reimbursement processes by assessing the drug's benefits compared to its alternatives alongside cost considerations [21]. In addition to clinical and economic aspects, increasingly other aspects related to the use of a particular medicine are considered. In certain cases, such as life-threatening conditions or orphan diseases, the assessment might find limited evidence or low cost-effectiveness, but the (unmet) need might be high as there are limited therapeutic alternatives. In this case, HTA can be used as a tool to support prioritization ensuring a more rational investment of funds, based on social needs and policy priorities [22]. HTA seems to be the preferred strategy as it addresses both price and appropriate indications for the use of the medicine and the relation between additional value and additional costs [4,22,23].

HTA might inform policymakers about different options and scenarios where there is more flexibility on pricing and reimbursement policies. Rather than an absolute yes or no to reimbursement, companies might need to bring in more evidence to showing benefit on certain conditions. The increasing number of high-priced drugs has started to challenge even wealthier countries to develop policies on how to improve access to medicines in an affordable way. Europe, for example, has set this issue high on their agenda [4,24]. This led to innovative ways of pricing and reimbursing pharmaceuticals, such as value based pricing or managed entry agreements [4,5,25]. These approaches, especially managed entry agreements, were created to enable access to (coverage/reimbursement of) a product subject to specified conditions, such as price negotiations. While this is a way

to provide access to the drug, it risks transparency and transferability at the global level [4,25]. We will discuss this further in this chapter.

The European Commission has financially supported several HTA projects to promote the collaboration between Member States (MS) in the European Union (EU) since 1993 [4]. The European Commission and Council of Ministers designated HTA as “a political priority” in 2004, recognizing «[...] an urgent need for establishing a sustainable European network on HTA» [26]. EUnetHTA has coordinated these activities since 2006. EUnetHTA is defined as a «network of government appointed organizations [from EU MS, EU-accession countries, plus European Economic Area (EEA) and European Free Trade Association (EFTA) countries] and a large number of relevant regional agencies and non-for-profit organizations that produce or contribute to HTA in Europe». The collaboration has already resulted in methodological guidelines and tools such as the HTA Core Model – a methodological framework for shared production and use of HTA information in the era of diagnostic technologies, medical and surgical interventions, drugs and screening technologies. The purpose is «to enable production of high quality HTA information in a structured format to support the production of local (national or regional) HTAs and re-use of existing information». HTA organizations use this model as the value framework when assessing technologies within the EU [27].

Since 2009, EUnetHTA collaborated with the European Union and the European Commission partners to administer joint assessments and implement the results. EUnetHTA has finished 20 joint assessments until 2015. This cooperation on HTA projects has the potential to increase the quality of HTA. An assessment can be done in two different ways; a rapid Relative Effectiveness Assessment (REA) and a full HTA. We can evaluate the incremental therapeutic value of technologies with a rapid REA; however, a full HTA has a broader perspective. A rapid REA covers the following domains: health problem and current use of technology, description and technical characteristics, safety and clinical effectiveness; furthermore, a full HTA also includes the following domains: costs and economic evaluation, ethical analysis, organizational aspects, patient and social aspects, and legal aspects [27].

Relative effectiveness is defined as «the extent to which an intervention does more good than harm compared with one or more alternative interventions under the usual circumstances of healthcare practice». Especially payers are more interested in evaluating the relative effectiveness of new healthcare technologies compared to standard care or other technologies, and have documented their preferred comparators [21]. This interest in relative effectiveness information in Europe is due to the early information need for guiding reimbursement and funding decisions about new health technologies [3-5,28].

EUnetHTA published a review about REA in 2011. According to this report, most countries surveyed use REA to support national reimbursement decisions of drugs, but the subject and methodology vary across countries due to the health system, reimbursement processes, the socio-cultural structure and the level of GDP per capita of the country [27].

15.5 How HTA Differs from One Setting to Another

The scope and methods of HTA may be adapted to the needs of a particular health system, but it is known that each country has its own priorities, sources and unique decision-making processes. Below we will give four country examples on how HTA structures change from setting to setting and discuss how they compare with regard to the decisions made with certain pharmaceuticals.

HTA in France

In France, HTA is governed and organized officially based on the legislations of the government and the SHI (Statutory Health Insurance or *Assurance Maladie* in French) [29]. The French government established the main French HTA organization, called HAS (French National Health Authority or *Haute Autorité de Santé* in French) in August 2004 [29,30]. The main goal of the HAS was determined as being the single organization which covers many activities aiming to improve the quality of health care and ensure equity within the health system [30]. In order to achieve this goal, this organization assesses drugs, reagents, tests, medical devices, practices and procedures as well as health programmes; develops guidelines; provides training and information about quality; accredits health care providers and certifies physicians [29,30]. As an independent (non-governmental) public institution, HAS has financial autonomy and collaborates with several partners such as governmental health agencies, national health insurance funds, research centres, societies of healthcare professionals and patients [30].

HAS has extensive in-house scientific expertise, nevertheless it is also authorized to undertake commissions external experts (e.g. academicians, professionals, other experts) [29,30]. HTA is done by the HAS before inclusion of new medicines on the positive list for reimbursement can occur [29]. After a health technology receives the regulatory approval from EMA (European Medicines Agency) or AFSSAPS (French Health Products Safety Agency or *Agence Française de Sécurité Sanitaire des Produits de Santé* in French), an HTA report is an obligation in order to be considered for pricing and reimbursement by French decision makers [29,30]. Necessary HTA is conducted by two specific commissions within the HAS [29]. The Transparency Commission (*Commission de la Transparence* in French) evaluates drugs, while CNEDIMTS (National Commission for the Evaluation of Medical Devices or *Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé* in French) evaluates medical devices and procedures [29]. Obligatory HTAs, which are done for all new health technologies by the aforementioned commissions based on the documents presented by the manufacturers before the market launch, have a direct influence on the reimbursement rate of SHI and a less direct influence on the price (statutory tariff) [29,30]. Two reviewers evaluate and criticize each HTA study, before it is discussed by the relevant commission. The HTA procedure in France may be classified into two steps [29,30]:

- First step is the assessment of the product's medical benefit or therapeutic value which is called SMR (*Service Medical Rendu* in French) [21,29,30]. This assessment is done in absolute terms for all different types of use of the product, based on its clinical efficacy and safety, its importance within the therapeutic strategy, existence or absence of its alternatives, severity of disease which is indicated to treat, type of the treatment (preventive, curative or symptomatic) and its impact on public health which reflects epidemiological issues and quality of life [29,30]. The SMR level of the health technologies (e.g. major or considerable, important, moderate, low or weak but justifying reimbursement, insufficient) play an important role with reimbursement decisions and the reimbursement rate (from 0 to 100%) decisions [29,30].
- The second step is the assessment of the product's relative medical benefit compared to similar alternatives which is called ASMR (Improvement in the Relative Medical Benefit or *Amélioration du Service Medical Rendu* in French) for drugs or ASA (Improvement in Expected Benefit or *Amélioration du Service Attendu* in French) for medical devices and procedures [21,29,30]. This assessment is done and a grade, based on the improvement in medical effectiveness over similar alternatives, is given by the Transparency Commission for drugs and CNEDIMTS for medical devices and procedures [29]. ASMR or ASA grades of the health technologies (e.g. 1 for "major improvement" or "life-saving health technology", 2 for "important improvement", 3 for "significant or moderate improvement", 4 for "minor improvement", 5 for "no improvement") affect the decisions on pricing explicitly [21,29,30]. Therefore, this step of the assessment incentivizes the manufacturers to provide sufficient data about their products [29].

The HAS commissions examine the documents of the manufacturers, reviews the existing literature systematically and eventually updates all previous decisions about existing health technologies once every five years [29].

Since 2013, another HAS commission called CEESP (Commission for Economic Evaluation and Public Health or *Commission d'Évaluation Économique et de Santé Publique* in French) conducts an economic assessment under specific conditions such as; having a health technology which is considered as ASMR/ASA grade 1, 2 or 3 and may influence SHI expenditure significantly by its price and/or its effect on health care services' organization, medical practices or coverage conditions of patients or having a health technology which have or is expected to have a 20 million Euros or higher turnover after two years on the market [29].

The Ministry of Health is the responsible body to commission the assessment of other technologies such as the necessary equipment for a procedure [29]. Waiting until any additional information becomes available, or asking for surveys or observational research, are possible advices which follow the HTA reports [29]. It is usual that the manufacturers finance the research [29]. However, the researchers should be independent from the financiers [29].

There are multiple criteria used in the appraisal process that is done by the Transparency Commission. The most important criteria for the opinion are actual benefit, improvement in actual benefit, and target population. There is a formal appeal process of 90 days

in which companies get the chance to appeal and contest the decision. The HAS makes a recommendation to UNCAM (National Union of Health Insurance Funds or *Union Nationale des Caisses d'Assurance Maladie* in French), which provides the Ministry of Health with a final recommendation about inclusion in the SHI [31].

HTA in the Netherlands

The health system of the Netherlands includes a social health insurance system in which public insurance is compulsory. Citizens older than 18 years pay a flat premium per year for the basic insurance, while people with low incomes are financially compensated. In addition, complementary (voluntary) insurance exists. Through the Health Insurance Act, citizens are entitled to a basic benefit package, although for some entitlements co-payments exist. Health insurers play an important role in implementing the Health Insurance Act, and they are obliged to accept each citizen that wants to pursue a health insurance with them [32].

In 2016, around 10% of GDP was spent on health care, while this was around 9% in 2007. The Health Insurance Act governs curative care, including primary care and hospital care. Around 60% of the health care budget (700 million Euros in 2016) is allocated to this part of health care [32,33].

The Ministry of Health, Welfare and Sports (VWS) is responsible for the content of the benefit package, which comprises essential medical care, medical aids as well as pharmaceuticals. The National Health Care Institute (ZIN) also plays an important role – it has a legal advisory task with regard to the benefit package; its Appraisal Committee (ACP) has an advisory role in coverage-decision-making, while the Ministry of Health makes the final decision.

HTA has been introduced in the Netherlands in the early 1980s. At that time, the Health Insurance Council (now ZIN) and the Ministry of Health became concerned about the rapid developments in health technology (e.g. transplantations, and IVF) and their impact on health care and society, especially in terms of cost. During the 1980s and the 1990s, a series of policy-oriented reports were published that either focused on HTA or included HTA as part of future policy in the Netherlands. All these reports recommended a strong program of HTA as part of Dutch health care. An important impetus for HTA in the Netherlands was the launch of a national HTA research program in 1988 [34]. The Ministry of Health funds the program, which is currently running for the years 2016-2018 and 2019-2021 [35]. The program has evolved over the years, from being a more academic program, towards a program that is addressing the needs of health care professionals, patients and decision-makers [36]. In 1991, the Committee on Choices in Health Care (*Commissie Dunning*) suggested to use HTA for coverage decision-making using four criteria: necessity, effectiveness, efficiency and whether or not the interventions can financial borne by the individual (affordability) [34]. Since 2006, the main role of ZIN is managing the benefit package of health care, and one of its tasks is to advice the Minister of Health about coverage decision-making. ZIN currently makes use of four criteria, clearly inspired by those set out by the Dunning Committee: necessity, effectiveness,

cost-effectiveness and feasibility. Franken et al [37] questions whether economic evaluation play an important role in the Dutch system as actual cases (e.g. orphan drugs for Pompe and Fabry disease) [6] showed that it seems rather difficult to put restrictions even though the economic evidence is clear. This situation might prove different in the near future as ZIN is in the process of further optimizing the current (appraisal) system, by further operationalizing the criteria necessity and cost-effectiveness, as well as using deliberative processes based on Daniels and Sabin's Accountability for Reasonableness framework [38].

HTA in Germany

Germany was relatively late compared to other European countries to engaging in HTA activities [39]. In the early years, HTA was mainly conducted by individual researchers. HTA has now become an official necessity in decision-making with regard to which health technology should be covered through SHIs (*Statutory Health Insurance*), as a result of the SHI Modernization Act, which was announced in 2014 [39,40].

Currently, the main organizations involved in HTA are IQWiG (Institute for Quality and Efficiency in Health Care or *Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen* in German) for assessment and G-BA (Federal Joint Committee or *Gemeinsamer Bundesausschuss* in German) for the appraisal [39,40]. The G-BA has a department which can provide scientific advice for assessment, but they almost never produce HTA reports.

The G-BA is a multisectoral committee, which consists of dentists, physicians and representatives of hospitals, (non-voting) patients and SHIs [40]. It has a responsibility to control coverage and limitations on prescribing in order to ensure efficiency in the system [40]. Therefore, it evaluates new examination and treatment methods, assesses new medicines, categorizes them into reference price groups and publishes clinical guidelines, which need to be presented to the Federal Ministry of Health for approval [40]. The G-BA decisions based on the level of additional benefit may be appealed based on evidence and legislation [40]. Additional benefit is determined by assessing mortality, morbidity and health related quality of life of the new medicine versus current standards, similar to France [41]. The G-BA makes the final decision publicly available. Most HTAs are conducted by IQWiG.

IQWiG is an independent institute, which was founded in 2004, to assess medical efficiency, quality and effectiveness [40]. Since the new Competition Enhancement Act was announced in 2008, formal cost-effectiveness analyses have become an indispensable part of the German system and IQWiG is authorized to assess cost-benefit ratios of medicines in Germany [40]. It prepares HTA reports either at G-BA requests or self-initialized (for non-pharmaceutical products) [40]. It does not have any decision-making powers and its advice to the G-BA (e.g. including or excluding health technologies into the SHI coverage) are not binding [39,40]. The most important criteria used in the assessment phase are patient relevant outcomes, including mortality, morbidity and health related quality of life as opposed to surrogate measures. Context and implementation issues are partly taken into account (e.g. prescribing restrictions for certain pharmaceutical prod-

ucts are investigated). IQWiG is forced by law to make the evidence report of the assessment publicly available [31]. IQWiG has an informal collaboration with HAS (French National Health Authority) and NICE (National Institute for Health and Care Excellence), which provides bilateral sharing of basic information and scientific evidence with France and the England (in the United Kingdom) [40].

HTA in England/Wales, UK (United Kingdom)

HTA processes are usually aimed to evaluate value for money and eventually inform health policy-making at the national level in the UK [42]. NICE (National Institute for Health and Care Excellence), which is an independent public body founded as a Special Health Authority in 1999, is the main organization which is responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health [42]. Therefore, it supplies national guidance on specific health technologies (e.g. drugs and medical devices) through its HTA processes and on clinical practice through its clinical guideline development processes based on existing evidence [42,43]. However, in course of time after its foundation, it has taken up further duties in the field of public health as well [42].

Purchasers in the UK have local freedom to choose which health technologies they will buy and they are not obliged to purchase only cost-effective health technologies [43]. In other words health technologies, which are not found cost-effective, may also be covered locally [43]. The NHS (National Health Service) organizations in England and Wales are obliged to finance drugs and therapies approved by NICE based on HTA reports since 2002 [42]. It is also an obligation for NHS organizations to revise their clinical management procedures when NICE clinical guidelines are published [42].

NICE is responsible with both the assessment and the appraisal. Once a technology is referred to NICE for evaluation, NICE writes a draft assessment report together with the Department of Health, including health outcomes and costs. After stakeholder consultations, the scope of the HTA is finalized and all consultees and others are invited to make a submission. The evidence provided by the manufacturer is then reviewed by an independent academic group [31]. The Appraisal Committee of NICE comprises of 20-25 members from diverse backgrounds and includes lay members. It is the Committee's role to appraise the evidence gathered in the assessment phase, including clinical effectiveness and health-related factors, cost-effectiveness, social value judgements and costs (savings) outside NHS or non-health gains. Additional criteria are taken into account for end of life medicines. The Committee summarizes the key evidence and their own view on the evidence, and provides a preliminary recommendation, which is open for consultation. Comments are considered in a second Appraisal Committee meeting, after which the final recommendation to the NHS follows.

There is evidence showing that NICE guidance may affect the market share of drugs, patient access to medicines, prescription attitudes and clinical practices [42]. Most of the drugs, which exist on the market of the UK, are assessed and relevant guidance is published by NICE [43]. Additionally, Northern Ireland, Scotland and Wales have their own

advisory organizations to provide recommendations about clinical effectiveness, cost-effectiveness and prescription of medicines with health care devolved in the United Kingdom [43]. SMC (Scottish Medicines Consortium) takes this responsibility in Scotland, while AWMSG (All Wales Medicines Strategy Group) does it in Wales. NHS boards in Scotland should act in line with SMC recommendations [43]; however, this may not always be possible in view of budgetary issues.

Comparison on HTA and Decision Outcomes in Different Settings

As described above, the way in which HTA bodies/programmes are organized and provide input to decision making differs between health systems. In some countries, the HTA body (e.g. NICE in the UK) or an advisory council (e.g. National Health Care Institute in the Netherlands) develops guidance and/or recommendations concerning reimbursement of health technology. In other countries, there is a strong separation between the assessment and appraisal procedure (e.g. in Germany, IQWiG provides the assessment and the national authority – G-BA, decides on the added benefit of pharmaceutical products). Other models also exist – e.g. in France, where HAS (*Haute Autorité de Santé*) is mainly responsible for providing recommendations regarding the reimbursement of pharmaceuticals. The CEPS (*Comité Économique des Produits de Santé*), also a separate body, is responsible for price negotiations with pharmaceutical companies.

Abbreviated indication	Brand name (generic)	HTA recommendation					
		Germany	The Netherlands	France	England/Wales	Scotland	Poland
Breast cancer	Eribulin	Equal benefit	Added benefit	Added benefit	Negative	Negative	Negative
Colorectal cancer	Aflibercept	Added benefit	Not assessed	Equal benefit	Negative	Negative	Positive
Gastric cancer	Tegafur/Gimeracil/Oteracil	Not assessed	Lesser benefit	Lesser benefit	Not assessed	Positive	Negative
Melanoma	Ipilimumab	Added benefit	Added benefit	Added benefit	Positive	Negative	Positive
Non-small cell lung cancer	Crizotinib	Equal benefit	Not assessed	Added benefit	Negative	Negative	Negative
Prostate cancer	Abiraterone	Added benefit	Equal benefit	Added benefit	Positive	Negative	Positive
Renal cell carcinoma	Axitinib	Added benefit	Not assessed	Added benefit	Positive	Negative	Positive

Table 1. Recommendation regarding (selected) oncology drugs having received marketing authorization (2011-2013) in selected EU countries [27,47]

With regard to the use of HTA in decision making, it can be observed that in addition to the level of clinical benefit and cost-effectiveness, increasingly other aspects are taken into account in the appraisal [44]. For orphan drugs different criteria might apply in either the assessment phase (e.g. France), the appraisal phase (e.g. The Netherlands) or both (e.g. Germany) [45]. The approach taken seems to be correlated with the institutional context and the organization making the recommendation or decision, the financing and governance of the health system, as well as the culture and values of a country [46]. Obviously, this might lead to different decisions. This can also be seen in the Table 1, in which selected countries used the same assessment results based on relative effectiveness (using EUnetHTA Core Model). The diverging results could also be due to the fact that the scope (comparators and cost considerations) and the methodology used vary across countries [47]. Allen et al [48] found similar results in a study on national reimbursement decisions in nine countries for more than 100 new active substances approved by the European Medicines Agency.

15.6 Ongoing Developments Impacting on the Role of HTA to Improve the Managed Entry of New Medicines

There have been particular issues with the funding of new medicines for Hepatitis C given the potential number of patients, the possibility of a cure for this chronic infectious disease, the high launch price in a number of countries with associated potential budget impact, as well as concerns with the high level of profitability in some countries at over 99.9% gross profit at the initial requested prices [49-51]. This has resulted in extensive negotiations for discounts as well as restricted use, including managed entry agreements, which is not in the best interests of patients or health authorities [50-54]. There have also been concerns and issues with increasing prices of new cancer medicines and those for orphan disease despite little evidence that new cancer medicines extend or improve life [4,5,55,57]. The cost of new medicines to treat patients with cancer have risen more than tenfold in the past decade despite the low cost of goods of some new cancer medicines, lower than publicized R&D costs as well as current levels of profitability [58-61]. High reimbursed prices for new cancer medicines has been helped by the emotive nature of the disease area, which has typically translated into greater leeway among payers for granting premium prices even for very modest improvements in patient outcomes [4-6,55,57,61-63]. These concerns have already resulted in requests for price moderation for new cancer medicines for future sustainability [61,64,65]. Health authorities, particularly those providing universal access, are increasingly concerned if prices continue to rise given the appreciable number of new cancer medicines in development [4,5,65-67]. A similar situation is also seen for new medicines for orphan diseases given ever increasing prices [4,5,68], with public pressure resulting in, for instance, new medicines for orphan diseases in the Netherlands funded up to 15 million Euros/QALY [69].

Having said this, independent drug information journals, particularly in Europe, believe very few new medicines are truly innovative; with the vast majority seen as similar in their impact on health, or only marginally better, than existing medicines [5,6,70,71]. Consequently, these new medicines should command lower or similar prices to existing standards; or at best only limited increases versus existing standards based on HTA as well as key pricing and reimbursement considerations [4,5,21,41,72]. However, currently concerns with the definition of innovation and value, as well as issues of priority, unmet need and emotion, cloud such discussions and deliberations [63,73-76]. This is a challenge for the future especially in Europe to maintain the ideals of equitable and comprehensive healthcare.

There have also been concerns with some of the marketing activities of pharmaceutical, especially if this leads to inappropriate prescribing which add to costs and/ or potential patient safety [3,77-83]. This includes issues of 'evergreening' of medicines further adding to costs without necessarily improving patient care [84]. However, there are ongoing moves to address key stakeholder concerns particularly regarding the promotion of new medicines [85-87]. This includes improving the core competencies and standards of pharmaceutical physicians [88,89]. In addition, educating physicians that patients enrolled into clinical trials may be different to those seen in routine clinical care, which can mean additional vigilance [3,90].

There are also concerns among some health authorities regarding risk sharing arrangements, or Managed Entry Agreements (MEAs), to improve the affordability of new medicines and reduce uncertainty [25]. These have to be balanced though against no reimbursement if no agreements are reached. These concerns include potential savings in reality, whether health systems have the ability to monitor patient outcomes in routine clinical practice, and the administrative burden and costs associated with such schemes [3,25,75,91-93]. However not surprisingly given rising prices for new medicines, the number of such arrangements has grown in recent years especially for new anti-cancer medicines, although this is not universal [4,25,94-96]. It is likely these schemes will continue, certainly in the short to medium term, given increasing financial pressures and limited alternatives [96,97]. However, this has to be balanced with the need for health authorities and pharmaceutical companies to publish the outcomes of such schemes against their objectives to guide future decision making. Currently, there is a paucity of such information [4,25].

Alongside this, there are also increasing concerns among payers across Europe regarding issues relating to the potential introduction of adaptive pathways for new medicines to accelerate access to new innovative medicines [98,99]. Key concerns include i) issues of payment, i.e. who will pay for the new medicine during its testing phase among patients and at what price, ii) where does the product liability lie prior to full marketing authorization, pricing and reimbursement, iii) how is innovation and unmet need defined, iv) how long are new medicines in the adaptive pathways process prior to full evaluation, v) whether such schemes are needed in reality with fast-track schemes for new medicines already in existence, vi) whether health authorities currently have the necessary ability to monitor the effectiveness and safety of new medicines in routine clinical care, vii) wheth-




Figure 1. Schematic representation of ongoing models across Europe to improve the managed entry of new medicines. Modified from [3-6,98,108-112]

AP = Adaptive Pathways; MEAs = Managed Entry Agreements; P&R = Pricing and Reimbursement; QIs = Quality Indicators

er payers have the necessary powers to disinvest in new medicines if found not to be cost-effective in reality and manufacturers are reluctant to lower prices. Additionally, if health authorities do not have the necessary IT systems, who would pay for their subsequent development [99]? However, the use of patient registries post launch have helped address issues of appropriateness and concerns with new medicines such as potentially increasing rates of infection and cancer with the use of biological medicines to treat immunological diseases such as rheumatoid arthritis and psoriasis. Such concerns have not proved to be the case in long term follow-up of these patients [100-106]. Long term follow-up of patients in public healthcare databases have also demonstrated significantly improved long-term graft survival in kidney transplant patients prescribed cyclosporine versus tacrolimus despite current beliefs [107].

These issues and concerns have resulted in the development of new models, especially among European countries, to better manage the entry of new medicines, which also includes potential new models for valuing new medicines for orphan diseases given current concerns [3-6,66,108]. The proposed models include the role of HTA. In addition, HTA activities are increasingly used to guide disinvestment activities, with monies transferred to fund more effective and/or more efficient medicines [18-20]. Discussion of disinvestment activities is outside the scope of this chapter. However as mentioned, there have been published case histories regarding the disinvestment of medicines from a number of countries [18]. More recently, the authorities in Brazil have published a new approach that also includes assessing the effectiveness and safety of potential medicines for disinvestment in the real world, adding robustness to any decisions [19].

New Models to Improve the Managed Entry of New Medicines

A three-stage model has been proposed, and is now being implemented, to improve the managed entry of new medicines especially from a health authority perspective [3-6,66,108,109] (Figure 1). The model begins with pre-launch activities including horizon scanning and forecasting, the potential development of quality indicators for new medicines, as well as including new medicines that could go through the proposed adaptive pathways program especially in Europe [98,109-111]. This will increasingly include in Europe potential new medicines going through the adaptive pathways scheme [98,99].

Peri-launch activities including a fuller assessment of the potential value, requested prices and likely reimbursement, with or without a managed entry agreement, of new medicines versus any preliminary evaluation pre-launch [5,21,66,94]. Post-launch activities include the evaluation of ongoing managed entry agreements including continuing assessment of the effectiveness and safety of new medicines in routine clinical practice as well as the monitoring of prescribing against agreed quality indicators and guidelines.

Pre-launch activities

Pre-launch activities include horizon scanning and budgeting activities [109]. Horizon scanning is seen and defined as «identifying new medicines or new uses of existing medicines that are expected to receive marketing authorization from the Regulatory Author-




Figure 2. Horizon scanning sequencing activities. Modified from [109,118,121]

ity in the near future and estimating their potential impact on patient care» [113-116]. Since 1999, 18 countries across continents including Europe have been collaborating under the EuroScan project [111,116-118]. Each member agency is unique in its approach; however, they all have a common goal of informing particularly health authorities and hospital managers about new and emerging technologies that could have a significant impact on their health system [104,117,119,120]. Typical activities regarding horizon scanning among leading Western countries, including leading Western European countries, are discussed in Figure 2.

Key filtration and information components of reports in European countries including Austria, Italy, Sweden and the UK are contained in Table 2.

Horizon scanning units can issue different reports as new medicines approach potential marketing authorization to further help health authorities in their planning [109,111]. This includes Italy (Table 3), with medicines selected based on an agreed filtration process (Table 2).

Criteria	Key considerations
Filtration Criteria	<ul style="list-style-type: none"> • Current status, e.g. how close to marketing authorization • Likely population size • Severity of the disease area in question/whether a current priority area • Ability to meaningfully improve patient outcomes/address a situation currently associated with appreciable morbidity and mortality – consequently potentially influence treatment guidelines • Potentially innovative way of treating current diseases/level of innovation • Possibility of safety concerns, e.g. dabigatran • Potential budget impact including the potential for savings; part of a new growing class of medicines • Potential for off-label use • Could potentially require reorganization of healthcare services • Likely media/public interest • Likely non-optimal introduction rate following marketing authorization • Potentially legal, ethical or politically interesting considerations
Key components of early assessment reports	<ul style="list-style-type: none"> • Description of the medicine including disease area and mode of action • Likely clinical need and size of the likely patient population(s) • Current treatment approaches and alternatives; and possible pipeline products • Summary of efficacy in Phase II and III studies (depending on availability and timing of the reports) • Current completed and ongoing studies • Likely budget impact as well as any early pharmacoeconomic assessment • Potential to monitor utilization post-launch against agreed guidance • Possible marketing approaches among companies

Table 2. Key filtration criteria and components of horizon scanning reports in Europe. Modified from [3,109,111,116-118]

Enhancing the robustness forecasts concerning the likely utilization and expenditure of new medicines is increasingly essential to improve subsequent planning and resource allocation given ever increasing pressure on resources [3,4]. One example combining a number of factors to improve budget forecasting, which involves multiple expert groups, is from Stockholm County Council in Sweden [110]. Their forecast with expert groups, including physicians, pharmacists and health authority personnel, involves assessing the likely role of new medicines as well as the future utilization of existing medicines. Regression analyses are conducted on aggregate sales data and predicted trends are adjusted for possible changes in the market including possible patent expiries, with implications for appreciably lowering the price of medicines, as well as potential chang-

Reports available 36 months before potential MA for selected medicines	Reports 18 months before potential MA for selected medicines	Report 12 months before potential MA for selected medicines
<p>The report provides data from Phase II trials as well as of ongoing Phase III trials of targeted medicines. These reports help identify areas of research of interest to the Italian NHS which are currently not being met by pharmaceutical companies.</p>	<p>These reports are essentially for internal purposes among regional health authorities in Italy. The reports critically assess available results of completed Phase III trials and their implications. They help identify and prioritize emerging medicines likely to have a clinical and economic impact on the Italian NHS.</p>	<p>These reports critically evaluate available efficacy and safety data on new agreed medicines. The Italian Unit assesses their possible level of innovation, possible place in therapy (target population) as well as the potential economic (budget) and social impact. The reports are seen as particularly useful for national and regional health authorities.</p>

Table 3. Different reports and their timescales from the Italian Horizon Scanning Project (IHSP) prior to potential EMA marketing authorization (MA). Modified from [109,111]

es in the reimbursement status of medicines [109,110,122]. All of these factors are combined into a yearly forecast, which is subsequently monitored to improve future forecasting [109,110,118].

These activities in Europe will grow with the potential introduction of new medicines under the adaptive pathways scheme [98]. Similarly, for any early access schemes where budgetary responsibility is borne by the payers rather than pharmaceutical companies. These potentially include conditional approval schemes to accelerate access to new medicines for serious debilitating or life-threatening conditions; however, there are concerns [123,124]. This is different to fast track schemes, which are already in existence [98].

Whilst proposed adaptive pathways are welcomed by European payers and their advisers to accelerate early access of new medicines, especially those for debilitating diseases and where currently limited or no therapies are available for treatment, there are still considerable concerns. These concerns have been summarized in a number of published papers [98,99,123,125,126], and include the fact that there will still be inequity in the availability of new medicines across Europe depending on potential prices. Payer HTA considerations for assessing potential prices for new medicines going through the adaptive pathways route will also need to evolve to consider how to effectively deal with increased uncertainty, and build this into their negotiations with pharmaceutical companies [99,127].

Peri-launch activities

As already mentioned in previous paragraphs, European countries typically adopt different approaches to the pricing and reimbursement of new medicines, which can poten-

tially be classified into those countries that assess the level of innovation of new medicines against existing standards using HTA principles as part of price negotiations such as Austria, France and Germany [4,5,21,128]. Alternatively, basing reimbursement and funding decisions on economic criteria such as cost/QALY with or without threshold levels [4,5,21,129,130]. Currently, only a minority of countries using economic principles set threshold levels [21]; with suggestions by some that threshold levels should be lowered for long term sustainability [131].

European health authorities are increasingly requesting Budget Impact Analyses (BIA) as part of health economic assessments for reimbursement/funding and formulary approval decisions [4,109]. This will help with future forecasting, building on current initiatives [109,110] as BIAs help estimate the possible financial consequences with the envisaged diffusion of new technologies into healthcare systems [132]. Key components of any budget impact analyses include [109,133]:

- The perspective of the budget holder/payer.
- The defined time horizon (which is typically up to 3 years).
- Clearly defining the setting.
- Expressing the results as undiscounted cost differences between the use of the new medicines and the current situation.
- Taking into account potential trade-offs in terms of healthcare resources taking account of the potential variable effectiveness of the new medicine in different populations, especially if there are likely to be differences in the patient populations in routine clinical care compared with the Phase III trials.

There are concerns though with the majority of published BIAs including issues of bias, which negatively impacts on their current usefulness to health authorities [134].

Peri-launch activities also increasingly include assessing possible managed entry agreements (MEAs), sometimes referred to as risk sharing arrangements or other definitions [25,91,94,95], especially in Europe. However as mentioned, there are increasing concerns with such schemes, whether financial based or outcome based, among health authority personnel [25,91,109]. A key consideration, especially for outcome based schemes, is the availability of IT systems to routinely collect data on the use, effectiveness and safety of new medicines as part of these schemes. The use of individual patient records or registries for each new medicine, as well as any paper based scheme, quickly becomes challenging for clinicians and other healthcare professionals [91]. However, these concerns have to be weighed against the potential benefits of MEAs including [91,94,109]:

- Improving the opportunity for reimbursement, especially if decision making includes economic considerations such as cost/QALY and/or strict pricing criteria for new medicines, and for 'payers' to work within defined budgets.
- Such schemes help limit the 'off label' use of new medicines and/ or indication creep in clinical practice.
- Potential for payers to only fund new medicines that produce the desired health gain and/or help target physician prescribing to those patients where health gain is greatest through for instance biomarkers and other strategies.

- Enhance the ability of health authorities to monitor the safety and effectiveness of new treatments in routine clinical practice, especially where patients may be more elderly and/or more co-morbid than those enrolled into Phase III clinical trials.

In addition, with respect to ultra-orphan medicines, given the complexities of R&D, conditional approval and reimbursement including managed entry schemes may be one way forward to enhance their reimbursement and funding [135]. However, a prerequisite should be the demonstration of a minimum significant clinical benefit within a reasonable time frame, with limited reliance on any surrogate measures [135].

Consequently, there is an urgent need for publications assessing the impact and usefulness of MEAs against agreed criteria to provide future direction.

There are also concerns with current approaches to the pricing of cancer medicines and those for orphan diseases leading to proposed changes. These are summarized in Sections “New Cancer Medicines” and “New Medicines for Orphan Diseases” below. New proposals are also being considered for gene therapies given their likely costs, which include annuity payments [136,137]. Debates regarding the funding of new gene therapies will continue as more are launched.

New cancer medicines

Concerns with increasing prices of new cancer medicines, the limited health gain of an appreciable number of them including potential ‘targeted treatments’, and the number in development [4,5,55,57,61,62,138], have resulted in suggestions for establishing minimum targets for stating whether new cancer medicines are an advance, or not, for pricing and funding justifications [139,140]. As a result, potentially address concerns that funding of new cancer medicines at high prices, with often limited health gain, has been enhanced by the emotive nature of the disease [63,141]. As a result, negatively impacting on available resources for other patient populations within finite budgets. Similar considerations exist where specific budgets have been assigned to new cancer medicines to the detriment of other disease areas [142]. However, such concerns with the potential impact on raising the bar for licensing and funding considerations are not universal [143,144].

Suggestions for advanced cancers center on minimum increases in additional survival, especially given concerns with surrogate markers such as progression free survival, and overall response, on their impact on overall survival [4,55,139,145-148]. These debates will continue, with HTA analyses playing an increasing role.

Other suggestions to help improve future pricing and reimbursement considerations in challenging areas include multi-stakeholder debates to better align the needs for robust evidence requirements, given concerns with surrogate markers, and a collectively shared definition and acceptance on what are clinically relevant benefits for patients and society across disease areas [149]. As a result, help better shape the concepts of value to improve pricing and reimbursement deliberations in the future and reduce current controversies. This is particularly important in the cancer area given the appreciable number of new cancer medicines in development, and their likely prices, coupled with considerable unmet need [5,16,67].

New medicines for orphan diseases

There is also increasing concern regarding the funding for new orphan medicines given ever increasing prices [4,5], despite potential offsets with risk sharing arrangements [135]. Such concerns are exacerbated by situations where new medicines for orphan diseases have been funded up to 15 million Euros/QALY the non-classic form of Pompe disease [69]. However, this is not always the case with ten (over 50%) of 19 orphan drugs available on the EMA website in November 2013, for which health economic data were available, met a threshold level of 30,000 GB£/QALY [150].

Such deliberations have resulted in the development of multicriteria decision analyses tools involving all key stakeholder groups [4-6,151,152]. Examples include the Transparent Value Framework developed via an EU initiative [6]. It is expected such developments will grow given the number of orphan medicines in development, including very targeted cancer therapies [67,153].

Post-launch activities

Post launch activities are increasing as payers and others wish to assess the effectiveness and value of new medicines in routine clinical care, building on examples in for instance France. This includes any assessment as part of adaptive pathways programmes or MEAs.

As mentioned, this has included assessing rates of infection and cancer with the use of biological medicines to treat immunological diseases such as rheumatoid arthritis and psoriasis [100-106], as well as assessing long-term graft survival in kidney transplant patients prescribed either cyclosporine or tacrolimus [107]. Other examples including assessing the appropriateness of prescribing, as well as the effectiveness and safety of new oral anti-coagulants such as dabigatran given early concerns [3,154-156] as well as the use and potential risks associated with medicines for weight loss [157]. Post launch activities also include risk management plans, which incorporate risk evaluation and mitigation strategies normally required by the EMA and FDA as part of any medicine approval process to help ensure that the benefits of any new medicine outweighs its risks [158,159].

Conclusion and Next Steps

It is likely that the managed entry of new medicines will become more formalized with increasing horizon scanning and budget activities before launch, especially with developments such as adaptive pathways. This will require an increasing role for HTA and the development of additional skills dealing with increasing uncertainty.

It is also likely that we will see developments in reimbursement decision making especially for new cancer medicines and those for orphan diseases, as well as new gene therapies. This is essential given their potential budget impact and continuing concern with available resources coupled with continuing unmet need. All key stakeholder groups should be part of such developments in the future.

15.7 References

1. HTAi – Health Technology Assessment international. What is HTA? Available at <https://www.htai.org/htai/what-is-hta/> (last accessed September 2017)
2. HTA glossary.net. Available at www.htaglossary.net (last accessed September 2017)
3. Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. *Front Pharmacol* 2013; 4: 39
4. WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Available at http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.pdf?ua=1 (last accessed September 2017)
5. Godman B, Oortwijn W, de Waure C, et al. Links between Pharmaceutical R&D Models and Access to Affordable Medicines. A Study for the ENVI Committee. European Union, 2016. Available at [http://www.europarl.europa.eu/RegData/etudes/STUD/2016/587321/IPOL_STU\(2016\)587321_EN.pdf](http://www.europarl.europa.eu/RegData/etudes/STUD/2016/587321/IPOL_STU(2016)587321_EN.pdf) (last accessed September 2017)
6. Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? *Expert Rev Clin Pharmacol* 2015; 8: 77-94
7. Akyurek EC. Global Budget as a Reimbursement Method in Health and Turkey. *Journal of Social Security* 2012; 2: 124-53
8. Tutar F, Kilinc N. Economic Development Potential of the Healthcare Market in Turkey and its Comparison with Examples from Different Countries. *Afyon Kocatepe University IIBF Journal* 2007; 9: 31-54
9. Dastan I, Cetinkaya V. Comparing Health Systems, Health Expenditures and Health Indicators in OECD Countries and Turkey. *Journal of Social Security* 2015; 1: 104-34
10. Oortwijn W, Mathijssen J, Banta D. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. *Health Policy* 2010; 95: 174-84
11. Banta D. The development of health technology assessment. *Health Policy* 2003; 63: 121-32
12. Banta D, Behney CJ. Office of Technology Assessment health program. *Int J Technol Assess Health Care* 2009; 25 Suppl 1: 28-32
13. Banta D, Johnson E. History of HTA: Introduction. *Int J Technol Assess Health Care* 2009; 25 Suppl 1: 1-6
14. BD – Business Dictionary. Available at <http://www.businessdictionary.com/definition/market-access.html> (last accessed September 2017)
15. PHARMAfield. Market Access in practice: do you have a strategy? Available at <https://www.pharmafield.co.uk/features/2008/11/Market-Access-in-practice-do-you-have-a-strategy> (last accessed September 2017)

16. Kaplan W, Wirtz V, Mantel-Teeuwisse A, et al. Priority Medicines for Europe and the World. 2013 Update. Available at http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf (last accessed September 2017)
17. Barham L. Market access: The impact of HTAs on strategy. *Eye on Pharma* 2011. Available at <http://social.eyeforpharma.com/commercial/market-access-impact-htas-strategy> (last accessed September 2017)
18. Parkinson B, Sermet C, Clement F, et al. Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review. *PharmacoEconomics* 2015; 33: 905-24
19. Guerra-Junior AA, Pires de Lemos LL, Godman B, et al. Health technology performance assessment: real-world evidence for public healthcare sustainability. *Int J Technol Assess Health Care* 2017; 33: 279-87
20. Brett J, Elshaug AG, Bhatia RS, et al. A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study. *Implementation Science* 2017; 12: 58
21. Paris V, Belloni A. Value in Pharmaceutical Pricing. Paris: OECD Publishing, 2013
22. Vogler S, Paris V, Ferrario A, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. *Appl Health Econ Health Policy* 2017; 15: 307-21
23. Drummond M, Jönsson B, Rutten F, et al. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. *Eur J Health Econ* 2011; 12: 263-71
24. European Commission. Council conclusions on innovation for the benefit of patients (204/C 438/06). Brussels: 6 December 2014
25. Ferrario A, Arāja D, Bochenek T, et al. The implementation of managed entry agreements in Central and Eastern Europe: Findings and implications. *Pharmacoeconomics* 2017; 35: 1271-85
26. The EUnetHTA. Available at <http://www.eunetha.eu/about-us/history> (last accessed September 2017)
27. Oortwijn W on behalf of the HTAi Policy Forum. From Theory To Action: Developments In Value Frameworks To Inform The Allocation of Health Care Resources. Background Paper 2017 Policy Forum. Available at https://www.htai.org/index.php?eID=tx_nawsecuredl&u=0&g=0&t=1514959761&hash=0e4dd72f37c05587b449805eaf40592edee96efd&file=fileadmin/HTAi_Files/Policy_Forum/HTAi_Policy_Forum_2017_Background_Paper.pdf (last accessed September 2017)
28. Towse A, Jonsson B, McGrath C, et al. Understanding Variations In Relative Effectiveness: A Health Production Approach. *Int J Technol Assess Health Care* 2015; 31: 363-70
29. Chevreur K, Berg Brigham K, Durand-Zaleski I, et al. France: Health system review. *Health Syst Transit* 2015; 17: 1-218
30. ISPOR Global Health Care Systems Road Map. France Pharmaceuticals, 2009. Available at <https://www.ispor.org/HTARoadMaps/France.asp> (last accessed September 2017)

31. Oortwijn W, Determann D, Schiffers K, et al. Towards integrated health technology assessment for improving decision-making in selected countries. *Value Health* 2017; 20: 1121-30
32. Ministry of Health, Welfare and Sport. Healthcare in the Netherlands. 2016. Available at https://www.eiseverywhere.com/file_uploads/0f57b7c2d0d94ff45769269d50876905_P4-HealthcareintheNetherlands.pdf (last accessed September 2017)
33. Schäfer W, Kroneman M, Boerma W, et al. The Netherlands: Health System Review. *Health Syst Transit* 2010; 12: v-xxvii, 1-228
34. Banta HD, Oortwijn W. The history of health technology assessment in the Netherlands. *Int J Technol Assess Health Care* 2009; 25 Suppl. 1: 143-7
35. ZonMw. Program on Health Care Efficiency Research. Available at <https://www.zonmw.nl/en/research-and-results/efficiency-studies/programmas/programme-detail/health-care-efficiency-research/> (last accessed September 2017)
36. Van der Wilt GJ, Rovers M, Oortwijn W, et al. Hospital-based HTA at Radboud University Medical Centre in the Netherlands: Welcome to Reality. In: Sampietro-Colom L, Martin J (eds.). *Hospital-Based Health Technology Assessment*. Switzerland: Springer International Publishing, 2016
37. Franken M, Koopmanschap M, Steenhoek A. Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? *Z Evid Fortbild Qual Gesundheitswes* 2014; 108: 383-9
38. Zorginstituut Nederland. Pakketadvies in de praktijk. Wikken en wegen voor een rechtvaardig pakket. Available at <https://www.zorginstituutnederland.nl/publicaties/rapport/2017/09/06/rapport-pakketadvies-in-de-praktijk-wikken-en-wegen-voor-een-rechtvaardig-pakket> (last accessed September 2017)
39. Busse R, Blümel M. Germany: health system review. *Health Syst Transit* 2014; 16: 1-296
40. ISPOR Global Health Care Systems Road Map. Germany Pharmaceutical, 2009. Available at <https://www.ispor.org/HTARoadMaps/Germany.asp> (last accessed September 2017)
41. Godman B, Paterson K, Malmstrom RE, et al. Improving the managed entry of new medicines: sharing experiences across Europe. *Expert Rev Pharmacoecon Outcomes Res* 2012; 12: 439-41
42. ISPOR Global Health Care Systems Road Map. United Kingdom (England and Wales) - Reimbursement Process, 2008. Available at <https://www.ispor.org/HTARoadMaps/UK.asp> (last accessed September 2017)
43. Cylus J, Richardson E, Findley L, et al. United Kingdom: Health system review. *Health Syst Transit* 2015; 17: 1-125
44. Tanios, N, Wagner M, Tony M, et al., and the International Task Force on Decision Criteria. Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. *Int J Technol Assess Health Care* 2013; 29: 456-65
45. Kawalec P, Sagan A, Pilc A. The correlation between HTA recommendations and reimbursement status in Europe. *Orphanet J Rare Dis* 2016; 11: 122

46. Torbica A, Drummond M, Ferré, F, et al. Economic evaluation and health technology assessment in Europe and USA. A comparative analysis. Executive Summary. MedtecHTA Work Package 4, 2015. Available at http://www.medtehta.eu/wps/wcm/connect/272245ac-ebec-4709-a7b1-35a8a6c9c8bd/ExecutiveSummary_+MedtecHTA+WP4_D4.1.pdf?MOD=AJPERES (last accessed September 2017)
47. Kleijnen S, Lipska I, Leonardo Alves T, et al. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. *Ann Oncol* 2016; 27: 1768-75
48. Allen N, Liberti L, Walker SR, et al. A comparison of reimbursement recommendations by European HTA agencies: is there opportunity for further alignment? *Front Pharmacol* 2017; 8: 384
49. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. *JAMA* 2014; 312: 593-4
50. Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. *BMC Infect Dis* 2014; 14 Suppl 6: S5
51. de Bruijn W, Ibanez C, Frisk P, et al. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. *Front Pharmacol* 2016; 7: 197
52. Andrieux-Meyer I, Cohn J, de Araujo ES, et al. Disparity in market prices for hepatitis C virus direct-acting drugs. *Lancet Glob Health* 2015; 3: e676-7
53. Liao JM, Fischer MA. Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics. *Am J Public Health* 2017; 107: 893-9
54. Barua S, Greenwald R, Grebely J, et al. Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Ann Intern Med* 2015; 163: 215-23
55. Wild C, Grossmann N, Bonanno PV, et al. Utilisation of the ESMO-MCBS in practice of HTA. *Ann Oncol* 2016; 27: 2134-6
56. Godman B, Wild C, Haycox A. Patent expiry and costs for anti-cancer medicines for clinical use. *Generics and Biosimilars Initiative Journal* 2017; 6: 105-6
57. Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. *BMJ* 2017; 359: j4530
58. Hill A, Redd C, Gotham D, et al. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. *BMJ open* 2017; 7: e011965
59. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. *Lancet Oncol* 2014; 15: e112-8
60. Prasad V, Mailankody S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. *JAMA Intern Med* 2017; 177: 1569-75

61. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. *Blood* 2013; 121: 4439-42
62. Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: Justum Pretium--the just price. *J Clin Oncol* 2013; 31: 3600-4
63. Haycox A. Why Cancer? *PharmacoEconomics* 2016; 34: 625-7
64. Tefferi A, Kantarjian H, Rajkumar SV, et al. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. *Mayo Clin Proc* 2015; 90: 996-1000
65. Ghinea H, Kerridge I, Lipworth W. If we don't talk about value, cancer drugs will become terminal for health systems. The Conversation, 2015. Available at <http://theconversation.com/if-we-dont-talk-about-value-cancer-drugs-will-become-terminal-for-health-systems-44072> (last accessed September 2017)
66. Matuszewicz W, Godman B, Pedersen HB, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. *Expert Rev Pharmacoecon Outcomes Res* 2015; 15: 755-8
67. EFPIA. Health and Wealth. Pharma industry's contribution to health and wealth
68. Cohen JP, Felix A. Are payers treating orphan drugs differently? *J Mark Access Health Policy* 2014; 2: 23513
69. Simoens S, Picavet E, Dooms M, et al. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. *Appl Health Econ Health Policy* 2013; 11: 1-3
70. Editorial Staff. New products and new indications in 2016: a system that favours imitation over the pursuit of real progress. *Rev Prescrire* 2017; 37: 132-6
71. Vitry AI, Shin NH, Vitre P. Assessment of the therapeutic value of new medicines marketed in Australia. *J Pharm Policy Pract* 2013; 6: 2
72. Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. *Expert Rev Pharmacoecon Outcomes Res* 2008; 8: 357-71
73. Prata WM, Silvestre R, Godman B, et al. A Critical Look at Innovation Profile and Its Relationship with Pharmaceutical Industry. *International Journal of Scientific Research and Management (IJSRM)* 2017; 5: 5934-48
74. Wonder MJ. Assessment of the therapeutic value of new medicines marketed in Australia. *J Pharm Policy Pract* 2013; 6: 7
75. Hollis A. Sustainable Financing of Innovative Therapies: A Review of Approaches. *PharmacoEconomics* 2016; 34: 971-80
76. Antonanzas F, Terkola R, Postma M. The Value of Medicines: A Crucial but Vague Concept. *PharmacoEconomics* 2016; 34: 1227-39
77. Cohen D. Dabigatran: how the drug company withheld important analyses. *BMJ* 2014; 349: g4670
78. Davis C, Abraham J. Is there a cure for corporate crime in the drug industry? *BMJ* 2013; 346: f755

79. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. *PLoS Medicine* 2010; 7: e1000352
80. Desai T, Dhingra V, Shariff A, et al. Quantifying the Twitter Influence of Third Party Commercial Entities versus Healthcare Providers in Thirteen Medical Conferences from 2011 – 2013. *PloS one* 2016; 11: e0162376
81. Fleischman W, Agrawal S, King M, et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. *BMJ* 2016; 354: i4189
82. Light DW, Lexchin J, Darrow JJ. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. *J Law Med Ethics* 2013; 41: 590-600
83. Civaner M. Sale strategies of pharmaceutical companies in a “pharmerging” country: the problems will not improve if the gaps remain. *Health policy* 2012; 106: 225-32
84. Vernaz N, Haller G, Girardin F, et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. *PLoS Med* 2013; 10: e1001460
85. Francer J, Izquierdo JZ, Music T, et al. Ethical pharmaceutical promotion and communications worldwide: codes and regulations. *Philos Ethics Humanit Med* 2014; 9: 7
86. Yu SY, Yang BM, Kim JH. New anti-rebate legislation in South Korea. *Appl Health Econ Health Policy* 2013; 11: 311-8
87. Brkicic LS, Godman B, Voncina L, et al. Initiatives to improve prescribing efficiency for drugs to treat Parkinson's disease in Croatia: influence and future directions. *Expert Rev Pharmacoecon Outcomes Res* 2012; 12: 373-84
88. Silva H, Stonier P, Buhler F, et al. Core competencies for pharmaceutical physicians and drug development scientists. *Front Pharmacol* 2013; 4: 105
89. Dubois DJ, Jurczynska A, Kerpel-Fronius S, et al. Fostering Competence in Medicines Development: The IFAPP Perspective. *Front Pharmacol* 2016; 7: 377
90. Joppi R, Cinconze E, Mezzalira L, et al. Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: a population-based study. *Eur J Intern Med* 2013; 24: 318-23
91. Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. *BMC Health Serv Res* 2010; 10: 153
92. Williamson S. Patient access schemes for high-cost cancer medicines. *The Lancet Oncology* 2010; 11: 111-2
93. Toumi M, Jaroslowski S, Sawada T, et al. The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate. *Appl Health Econ Health Policy* 2017; 15: 5-11
94. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels: EMiNet, 2013. Available at <http://eprints.lse.ac.uk/50513> (last accessed September 2017)

95. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. *Soc Sci Med* 2015; 124: 39-47
96. Carlson JJ, Chen S, Garrison LP, Jr. Performance-Based Risk-Sharing Arrangements: An Updated International Review. *Pharmacoeconomics* 2017; 35: 1063-72
97. Garattini L, Curto A. Performance-Based Agreements in Italy: 'Trendy Outcomes' or Mere Illusions? *Pharmacoeconomics* 2016; 34: 967-9
98. Ermisch M, Bucsecs A, Vella Bonanno P, et al. Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. *Front Pharmacol* 2016; 7: 305
99. Vella Bonanno P, Ermisch M, Godman B, et al. Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. *Front Pharmacol* 2017; 8: 497
100. Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. *Ann Rheum Dis* 2017; 76: 386-91
101. Raaschou P, Simard JF, Asker Hagelberg C, et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. *BMJ* 2016; 352: i262
102. Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. *Ann Rheum Dis* 2017; 76: 105-11
103. Iskandar IY, Ashcroft DM, Warren RB, et al. Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis. *Br J Dermatol* 2017; 177: 1410-21
104. Garcia-Doval I, Cohen AD, Cazzaniga S, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. *J Am Acad Dermatol* 2017; 76: 299-308.e16
105. Davila-Seijo P, Garcia-Doval I, Naldi L, et al. Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. *Acta Derm Venereol* 2017; 97: 516-8
106. Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. *J Rheumatol* 2012; 39: 1179-84
107. Gomes RM, Guerra Junior AA, Lemos LL, et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. *Expert Rev Clin Pharmacol* 2016; 9: 991-9
108. Permanand G, Pedersen H. Managing new premium-priced medicines in Europe. *J Pharm Policy Pract* 2015; 8(Suppl 1): K2

109. Godman B, Joppi R, Bennie M, et al. Managed introduction of new drugs. In Elseviers M, Wettermark B, et al (eds). *Drug Utilization Research: Methods and Applications*. Chichester: John Wiley & Sons, 2016
110. Wettermark B, Persson ME, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. *BMC Health Serv Res* 2010; 10: 128
111. Joppi R, Dematte L, Menti AM, et al. The Italian Horizon Scanning Project. *Eur J Clin Pharmacol* 2009; 65: 775-81
112. Campbell SM, Godman B, Diogene E, et al. Quality indicators as a tool in improving the introduction of new medicines. *Basic Clin Pharmacol Toxicol* 2015; 116: 146-57
113. Wettermark B, Godman B, Eriksson C, van Ganse E, Garattini S, Joppi R, et al. Einführung neuer Arzneimittel in europäische Gesundheitssysteme (Introduction of new medicines into European healthcare systems). *GGW* 2010; 10: 24-34
114. Wild C, Langer T. Emerging health technologies: informing and supporting health policy early. *Health policy* 2008; 87: 160-71
115. Wild C, Simpson S, Douw K, et al. Information service on new and emerging health technologies: identification and prioritization processes for a European union-wide newsletter. *Int J Technol Assess Health Care* 2009; 25 Suppl 2: 48-55
116. Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United kingdom. *Int J Technol Assess Health Care* 2012; 28: 308-14
117. Nachtnebel A, Geiger-Gritsch S, Hintringer K, et al. Scanning the horizon: development and implementation of an early awareness system for anticancer drugs in Austria. *Health policy* 2012; 104: 1-11
118. Eriksson E, Wettermark B, Persson M, et al. The Early Awareness and Alert System in Sweden: History and Current Status. *Front Pharmacol* 2017; 8: 674
119. EuroScan International Network, A toolkit for the identification and assessment of new and emerging health technologies. Birmingham: EuroScan International Network, 2014
120. Martino OI, Ward DJ, Packer C, et al. Innovation and the burden of disease: retrospective observational study of new and emerging health technologies reported by the EuroScan Network from 2000 to 2009. *Value Health* 2012; 15: 376-80
121. Nachtnebel A, Breuer J, Willenbacher W, et al. Looking back on 5 years of horizon scanning in oncology. *Int J Technol Assess Health Care* 2016; 32: 54-60
122. Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. *Expert Rev Pharmacoecon Outcomes Res* 2009; 9: 65-83
123. Davis C, Lexchin J, Jefferson T, et al. Adaptive pathways to drug authorisation: adapting to industry? *BMJ* 2016; 354: i4437
124. Banzi R, Gerardi C, Bertele V, et al. Approvals of drugs with uncertain benefit-risk profiles in Europe. *Eur J Intern Med* 2015; 26: 572-84
125. Joppi R, Gerardi C, Bertele V, et al. Letting post-marketing bridge the evidence gap: the case of orphan drugs. *BMJ* 2016; 353: i2978

126. Hawkes N. Specialists attack drug agency's fast track approval scheme. *BMJ* 2016; 353: i3060
127. Grimm SE, Strong M, Brennan A, et al. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. *Pharmacoeconomics* 2017; 35: 1287-96
128. Godman B, Campbell S, Suh HS, et al. Ongoing Measures to Enhance Prescribing Efficiency Across Europe: Implications for Other Countries. *J Health Tech Assess* 2013; 1: 27-42
129. Godman B, Gustafsson LL. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. *Appl Health Econ Health Policy* 2013; 11: 79-82
130. Svensson M, Nilsson FO, Arnberg K. Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness. *PharmacoEconomics* 2015; 33: 1229-36
131. Raftery JP. NICE's cost-effectiveness range: should it be lowered? *PharmacoEconomics* 2014; 32: 613-5
132. ISPOR. ISPOR Task Force on Good Research Practices. Report of the ISPOR Task Force on Good Research Practices – Budget Impact Analysis. Available at http://www.ispor.org/workpaper/BudgetImpactAnalysis/BIA_TF0906.asp (last accessed September 2017)
133. van de Vooren K, Duranti S, Curto A, et al. A critical systematic review of budget impact analyses on drugs in the EU countries. *Appl Health Econ Health Policy* 2014; 12: 33-40
134. Faleiros DR, Alvares J, Almeida AM, et al. Budget impact analysis of medicines: updated systematic review and implications. *Expert Rev Pharmacoecon Outcomes Res* 2016; 16: 257-66
135. Schlander M, Garattini S, Kolominsky-Rabas P, et al. Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement. *J Mark Access Health Policy* 2016; 4
136. Jorgensen J, Kefalas P. Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test. *J Mark Access Health Policy* 2017; 5: 1355203
137. Marsden G TA, Pearson SD, Dreitlein W, et al. GENE THERAPY: Understanding the Science, Assessing the Evidence, and Paying for Value. Office of Health Economics, 2017. Available at <https://www.ohe.org/news/new-publication-gene-therapy-understanding-science-assessing-evidence-and-paying-value> (last accessed September 2017)
138. Godman B, Finlayson AE, Cheema PK, et al. Personalizing health care: feasibility and future implications. *BMC medicine* 2013; 11: 179
139. Ferguson JS, Summerhayes M, Masters S, et al. New treatments for advanced cancer: an approach to prioritization. *Br J Cancer* 2000; 83: 1268-73
140. Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-

- cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). *Ann Oncol* 2015; 26: 1547-73
141. Pauwels K, Huys I, Casteels M, et al. Market access of cancer drugs in European countries: improving resource allocation. *Target Oncol* 2014; 9: 95-110
 142. [No authors listed]. New 50 million pound cancer fund already intellectually bankrupt. *Lancet* 2010; 376: 389
 143. Barron A, Wilsdon T. Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer. *Pharmaceut Med* 2016; 30: 321-6
 144. Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. *J Clin Oncol* 2009; 27: 5868-73
 145. Henshall C, Samson L, Eichler H-G, et al. Understanding the Role and Evidence Expectations of Health Technology Assessment and Coverage/Payer Bodies: What Are They Looking for, and How and Why Does This Differ From What Regulators Require? *Therapeutic Innovation & Regulatory Science* 2013; 48: 341-6
 146. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet* 2014; 384: 164-72
 147. Prasad V, Kim C, Burotto M, et al. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses. *JAMA Intern Med* 2015; 175: 1389-98
 148. Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. *JAMA Intern Med* 2013; 173: 611-2
 149. Kleijnen S, Lipska I, Leonardo Alves T, et al. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. *Ann Oncol* 2016; 27: 1768-75
 150. Picavet E, Cassiman D, Simoens S. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses. *J Clin Pharm Ther* 2015; 40: 304-7
 151. Hughes-Wilson W, Palma A, Schuurman A, et al. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? *Orphanet J Rare Dis* 2012; 7: 74
 152. Gilabert-Perramon A, Torrent-Farnell J, Catalan A, et al. Drug Evaluation And Decision Making In Catalonia: Development And Validation Of A Methodological Framework Based On Multi-Criteria Decision Analysis (Mcdca) For Orphan Drugs. *Int J Technol Assess Health Care* 2017; 33: 111-20
 153. Mullard A. 2011 FDA drug approvals. *Nat Rev Drug Discov* 2012; 11: 91-4
 154. Godman B, Malmstrom RE, Diogene E, et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. *Front Pharmacol* 2014; 5: 109
 155. Larock AS, Mullier F, Sennesael AL, et al. Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. *Ann Pharmacother* 2014; 48: 1258-68

156. Troncoso A, Diogene E. Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. *Eur J Clin Pharmacol* 2014; 70: 249-50
157. Forslund T, Raaschou P, Hjerdahl P, et al. Usage, risk, and benefit of weight-loss drugs in primary care. *J Obes* 2011; 2011: 459263
158. EMA. Guideline on Safety and Efficacy Follow-up - Risk Management of Advanced Therapy Medicinal Products. 2008. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500006326.pdf (last accessed September 2017)
159. EMA. CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a Pandemic Influenza Vaccine. 2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500051739.pdf (last accessed September 2017)